Evidence map›Paper›PMID 36480120›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2023

Malassezia spp. and Candida spp. from patients with psoriasis exhibit reduced susceptibility to antifungals.

Rossana de Aguiar Cordeiro, Ane Teles Reis, Xinaida Taligare Vasconcelos Lima, Ana Raquel Colares de Andrade, Ana Luiza Ribeiro Aguiar, Fernando Victor Monteiro Portela, Lívia Maria Galdino Pereira, Santiago Gonçalves Bezerra Moura, Bruno Nascimento da Silva, Reginaldo Gonçalves de Lima-Neto and 3 more

Open access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Oxymatrine amelioratesMycology · 2026
    Article
  2. Does the use of topical azoles have an impact on antifungal resistance?The Journal of antimicrobial chemotherapy · 2025
    Article
  3. Article
  4. Review
  5. In Vitro Activity of Farnesol againstAnimals : an open access journal from MDPI · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Rossana de Aguiar Cordeiro *Federal University of Ceará, Fortaleza, Brazil. rossanacordeiro@ufc.br.ORCID http://orcid.org/0000-0001-8386-2180
Ane Teles Reis *Federal University of Ceará, Fortaleza, Brazil.
Xinaida Taligare Vasconcelos LimaFederal University of Ceará, Fortaleza, Brazil.
Ana Raquel Colares de AndradeFederal University of Ceará, Fortaleza, Brazil.
Ana Luiza Ribeiro AguiarFederal University of Ceará, Fortaleza, Brazil.
Fernando Victor Monteiro PortelaFederal University of Ceará, Fortaleza, Brazil.
Lívia Maria Galdino PereiraFederal University of Ceará, Fortaleza, Brazil.
Santiago Gonçalves Bezerra MouraFederal University of Ceará, Fortaleza, Brazil.
Bruno Nascimento da SilvaFederal University of Ceará, Fortaleza, Brazil.
Reginaldo Gonçalves de Lima-NetoFederal University of Pernambuco, Recife, Brazil.
Débora Castelo-Branco Souza Collares MaiaFederal University of Ceará, Fortaleza, Brazil.
Marcos Fábio Gadelha RochaFederal University of Ceará, Fortaleza, Brazil.
José Júlio Costa SidrimFederal University of Ceará, Fortaleza, Brazil.
Universidade Federal do Ceará · BRUniversidade Estadual do Ceará · BRUniversidade Federal de Pernambuco · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 430193/2018-1
6 · The paper itself

Abstract

introductionPsoriasis is a chronic inflammatory disease that affects over 125 million people worldwide. Many studies have shown the importance of the microbiome for psoriasis exacerbation.

aimExplore the fungal load and species composition of cultivable yeasts on the skin of psoriatic patients (PP) and healthy volunteers living in a tropical area and evaluate the susceptibility to antifungals. METHODOLOGY: A cross-sectional study with 61 participants (35 patients and 26 healthy controls) was performed during August 2018 and May 2019. Clinical data were collected from patient interviewing and/or medical records review. Samples were collected by swabbing in up to five anatomic sites. Suggestive yeast colonies were counted and further identified by phenotypical tests, PCR-REA, and/or MALDI-TOF. Susceptibility of Malassezia spp. and Candida spp. to azoles, terbinafine, and amphotericin B was evaluated by broth microdilution.

resultsNearly 50% of the patients had moderate to severe psoriasis, and plaque-type psoriasis was the most common clinical form. Yeast colonies count was significantly more abundant among PP than healthy controls. Malassezia and Candida were the most abundant genus detected in all participants. Higher MIC values for ketoconazole and terbinafine were observed in Malassezia strains obtained from PP. Approximately 42% of Candida isolates from PP showed resistance to itraconazole in contrast to 12.5% of isolates from healthy controls. MIC values for fluconazole and amphotericin B were significantly different among Candida isolates from PP and healthy individuals.

conclusionThis study showed that Malassezia and Candida strains from PP presented higher MIC values to widespread antifungal drugs than healthy individuals.

Indexed as

MalasseziaPsoriasisAmphotericin BAntifungal AgentsCandidaCross-Sectional StudiesDrug Resistance, FungalFluconazoleHumansItraconazoleMicrobial Sensitivity TestsSaccharomyces cerevisiaeTerbinafineAmphotericin BAntifungal AgentsFluconazoleItraconazoleTerbinafineAntifungal susceptibilityMycobiotaPsoriasisYeast

Identifiers

PMID36480120
PMCPMC9944151
OpenAlexW4310962334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.